BioCryst Pharmaceuticals Inc. [NASDAQ: BCRX] stock went on an upward path that rose over 0.44% on Tuesday, amounting to a one-week price decrease of less than -2.22%. The company report on July 10, 2021 that BioCryst Reports 96-week Data from APeX-2 Showing ORLADEYO®(berotralstat) Reduced HAE Attack Rate by 80 Percent from Baseline.
—Multiple data presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2021 highlight durability of effect and long-term safety of ORLADEYO—.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that hereditary angioedema (HAE) patients who were randomized to receive 150 mg of oral, once-daily ORLADEYO® (berotralstat) at the start of the APeX-2 trial had an 80 percent average reduction in their mean attack rate per month during weeks 25-96 of the trial, compared to baseline. Median attack rates also decreased from 2.7 attacks/month at baseline to 0.0 attacks per month in 16 of 17 months through the same period.
Over the last 12 months, BCRX stock rose by 220.61%. The one-year BioCryst Pharmaceuticals Inc. stock forecast points to a potential upside of 11.29. The average equity rating for BCRX stock is currently 2.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $2.80 billion, with 177.34 million shares outstanding and 176.16 million shares in the current float. Compared to the average trading volume of 3.70M shares, BCRX stock reached a trading volume of 1736501 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on BioCryst Pharmaceuticals Inc. [BCRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BCRX shares is $17.89 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BCRX stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cowen have made an estimate for BioCryst Pharmaceuticals Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on March 01, 2021. While these analysts kept the previous recommendation, JP Morgan raised their target price to Overweight. The new note on the price target was released on September 29, 2020, representing the official price target for BioCryst Pharmaceuticals Inc. stock.
The Average True Range (ATR) for BioCryst Pharmaceuticals Inc. is set at 0.75, with the Price to Sales ratio for BCRX stock in the period of the last 12 months amounting to 87.53.
BCRX Stock Performance Analysis:
BioCryst Pharmaceuticals Inc. [BCRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.22. With this latest performance, BCRX shares dropped by -5.03% in over the last four-week period, additionally plugging by 111.32% over the last 6 months – not to mention a rise of 220.61% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BCRX stock in for the last two-week period is set at 49.69, with the RSI for the last a single of trading hit 45.57, and the three-weeks RSI is set at 52.60 for BioCryst Pharmaceuticals Inc. [BCRX]. The present Moving Average for the last 50 days of trading for this stock 15.06, while it was recorded at 16.03 for the last single week of trading, and 9.79 for the last 200 days.
Insight into BioCryst Pharmaceuticals Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and BioCryst Pharmaceuticals Inc. [BCRX] shares currently have an operating margin of -952.90 and a Gross Margin at +90.59. BioCryst Pharmaceuticals Inc.’s Net Margin is presently recorded at -1026.35.
Return on Total Capital for BCRX is now -131.36, given the latest momentum, and Return on Invested Capital for the company is -195.22. Return on Equity for this stock declined to -1,925.37, with Return on Assets sitting at -71.69. Additionally, BCRX Total Debt to Total Capital is recorded at 114.21, with Total Debt to Total Assets ending up at 46.24.
Reflecting on the efficiency of the workforce at the company, BioCryst Pharmaceuticals Inc. [BCRX] managed to generate an average of -$743,146 per employee. Receivables Turnover for the company is 1.16 with a Total Asset Turnover recorded at a value of 0.07.BioCryst Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.70 and a Current Ratio set at 2.70.
BCRX Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BCRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for BioCryst Pharmaceuticals Inc. go to 19.90%.
BioCryst Pharmaceuticals Inc. [BCRX] Insider Position Details
There are presently around $1,661 million, or 60.30% of BCRX stock, in the hands of institutional investors. The top three institutional holders of BCRX stocks are: BLACKROCK INC. with ownership of 16,241,775, which is approximately -0.111% of the company’s market cap and around 0.40% of the total institutional ownership; BAKER BROS. ADVISORS LP, holding 12,710,818 shares of the stock with an approximate value of $201.72 million in BCRX stocks shares; and VANGUARD GROUP INC, currently with $153.94 million in BCRX stock with ownership of nearly -16.374% of the company’s market capitalization.
Positions in BioCryst Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 100 institutional holders increased their position in BioCryst Pharmaceuticals Inc. [NASDAQ:BCRX] by around 18,149,183 shares. Additionally, 100 investors decreased positions by around 33,716,256 shares, while 18 investors held positions by with 52,773,033 shares. The mentioned changes placed institutional holdings at 104,638,472 shares, according to the latest SEC report filing. BCRX stock had 43 new institutional investments in for a total of 11,385,675 shares, while 32 institutional investors sold positions of 7,197,868 shares during the same period.